Nasdaq grants Iveda 180-day extension to March 1, 2027 to regain $1.00 bid price compliance

Iveda Solutions, Inc.

Nasdaq granted additional 180-day period through March 1, 2027 to cure minimum bid price deficiency under Rule 5550(a)(2).
To regain compliance, IVDA must close at or above $1.00 for at least 10 consecutive business days during the extension.
Iveda may consider a reverse stock split if needed; no decision announced yet.
No immediate effect on listing; common stock continues trading on Nasdaq Capital Market under symbol IVDA.
Company cites commercial progress in AI video intelligence, autonomous systems, and IvedaAir launch during extension.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.